321 related articles for article (PubMed ID: 28467787)
21. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin.
El Omari N; Lee LH; Bakrim S; Makeen HA; Alhazmi HA; Mohan S; Khalid A; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Aug; 164():114774. PubMed ID: 37224749
[TBL] [Abstract][Full Text] [Related]
23. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
24. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
25. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Son DS; Wilson AJ; Parl AK; Khabele D
Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
[TBL] [Abstract][Full Text] [Related]
26. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin for the treatment of non-Hodgkin's lymphoma.
Yazbeck VY; Grant S
Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
[TBL] [Abstract][Full Text] [Related]
28. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.
Coward WR; Watts K; Feghali-Bostwick CA; Jenkins G; Pang L
Mol Cell Biol; 2010 Jun; 30(12):2874-86. PubMed ID: 20404089
[TBL] [Abstract][Full Text] [Related]
29. Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
Chua MJ; Arnold MS; Xu W; Lancelot J; Lamotte S; Späth GF; Prina E; Pierce RJ; Fairlie DP; Skinner-Adams TS; Andrews KT
Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):42-50. PubMed ID: 28107750
[TBL] [Abstract][Full Text] [Related]
30. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
31. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
[TBL] [Abstract][Full Text] [Related]
32. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
Paillas S; Then CK; Kilgas S; Ruan JL; Thompson J; Elliott A; Smart S; Kiltie AE
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):212-221. PubMed ID: 31987970
[TBL] [Abstract][Full Text] [Related]
33. Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner.
Schuliga M; Read J; Blokland KEC; Waters DW; Burgess J; Prêle C; Mutsaers SE; Jaffar J; Westall G; Reid A; James A; Grainge C; Knight DA
Clin Sci (Lond); 2020 Apr; 134(7):889-905. PubMed ID: 32219338
[TBL] [Abstract][Full Text] [Related]
34. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.
Sun WJ; Huang H; He B; Hu DH; Li PH; Yu YJ; Zhou XH; Lv Z; Zhou L; Hu TY; Yao ZC; Lu MD; Shen X; Zheng ZQ
Biochem Pharmacol; 2017 Mar; 127():90-100. PubMed ID: 28012958
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Pang M; Zhuang S
J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
[TBL] [Abstract][Full Text] [Related]
37. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
38. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
39. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.
Wang Y; Yella JK; Ghandikota S; Cherukuri TC; Ediga HH; Madala SK; Jegga AG
Ther Adv Respir Dis; 2020; 14():1753466620971143. PubMed ID: 33167785
[TBL] [Abstract][Full Text] [Related]
40. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
